![](/congress115th/20190108202849im_/https://cancergenome.nih.gov/PublishedContent/Images/images/Cell_PanCan_FB cropped carousel.jpg)
TCGA's Pan-Cancer Atlas
TCGA’s Pan-Cancer Atlas of insights and overarching themes on cancer culminates the 10+ year project.
![](/congress115th/20190108202849im_/https://cancergenome.nih.gov/PublishedContent/Images/images/testicular 346px.jpg)
TCGA's Testicular Germ Cell Tumor Study
TCGA network researchers identify molecular characteristics that classify testicular germ cell tumor types, including a separate subset of seminomas defined by KIT mutations. This provides a set of candidate biomarkers for risk stratification and potential therapeutic targeting.
![](/congress115th/20190108202849im_/https://cancergenome.nih.gov/PublishedContent/Images/images/TCGA Sarcoma graphical abstract.png)
TCGA’s Study of Soft Tissue Sarcoma
TCGA’s analysis of six major types of adult soft tissue sarcomas reveals frequent copy number alterations, low mutational loads, and a diverse array of underlying molecular mechanisms. Certain sarcomas may benefit from immunotherapy.
![Cancers Selected For Study map](/congress115th/20190108202849im_/https://cancergenome.nih.gov/PublishedContent/Images/SharedItems/Images/TCGA_tcz_cancerstudy_image_enlarge.jpg)
Cancers Selected for Study
The Cancer Genome Atlas researchers are mapping the genetic changes in 33 cancers. Find out which cancers have been selected for study, the criteria for selection and the scientific questions being asked about each cancer.
-
TCGA in Action
-
December 2016
CASE STUDY: A Researcher Mined TCGA Data to Study Her Own Ovarian Cancer
Faced the bleak prognosis associated with stage IIIC ovarian cancer, Shirley Pepke, Ph.D., used her computational biology background to study her own cancer in comparison to TCGA data. Pepke has now been in remission for a year. Image Credit: Gus Ruelas/USC -
September 2016
CASE STUDY: TCGA Data Leveraged for Developing FDA-Designated Breakthrough Therapy
Pharmaceutical company Loxo Oncology used TCGA data in the research that led them to develop FDA-designated Breakthrough Therapy LOXO-101, a promising new targeted therapy.
More Stories
-
News and Announcements
- June 12, 2018
Integrated Molecular Characterization of Testicular Germ Cell Tumors
TCGA network researchers identify molecular characteristics that classify testicular germ cell tumor types, including a separate subset of seminomas defined by KIT mutations. This provides a set of candidate biomarkers for risk stratification and potential therapeutic targeting. - May 01, 2018
TCGA Releases The Pan-Cancer Atlas
TCGA’s Pan-Cancer Atlas of insights and overarching themes on cancer culminates the 10+ year project.
View All
-
Research Briefs
-
June 2017
TCGA Data Used to Study Ties Between Tumor Genetics and Evolutionary History
A study using TCGA data investigated the theory that cancer cells revert to ancient cellular processes. The researchers found repression of newer cellular processes and activation of older genes, providing insight into the hallmarks of cancer common across different types.
View All
-
Perspectives
-
October 2015
Genomic Contributions to Breast Cancer Disparities
Dr. Tanya Keenan shares her study's findings on the genomic contributions to breast cancer disparities and advocates for inclusion in breast cancer research.
View All